Agenus shared on LinkedIn:
“At ESMO26, three investigator-sponsored BOT+BAL posters will span neoadjuvant colorectal cancer, refractory MSS metastatic CRC and advanced sarcoma.
The pan-tumor NEOASIS study adds to the evaluation of BOT+BAL before surgery as Agenus advances its neoadjuvant strategy.”